The risk of osteoporosis in patients with asthma.

IF 1.8 Q3 RESPIRATORY SYSTEM European Clinical Respiratory Journal Pub Date : 2020-05-19 eCollection Date: 2020-01-01 DOI:10.1080/20018525.2020.1763612
Indumathi Kumarathas, Torben Harsløf, Charlotte Uggerhøj Andersen, Bente Langdahl, Ole Hilberg, Leif Bjermer, Anders Løkke
{"title":"The risk of osteoporosis in patients with asthma.","authors":"Indumathi Kumarathas,&nbsp;Torben Harsløf,&nbsp;Charlotte Uggerhøj Andersen,&nbsp;Bente Langdahl,&nbsp;Ole Hilberg,&nbsp;Leif Bjermer,&nbsp;Anders Løkke","doi":"10.1080/20018525.2020.1763612","DOIUrl":null,"url":null,"abstract":"<p><p>It is well-known that use of continuous systemic corticosteroids (SG) affects bone metabolism, bone mineral density (BMD), and ultimately increases the risk of osteoporosis. In patients with asthma, on the other hand, the effects of long-term high-dose inhaled corticosteroids (ICS) on BMD and risk of osteoporotic fractures is controversial. The reasons for this inconsistency could be explained by the fact that only few long-term studies investigating the effect of ICS in patients with asthma exist. The studies are characterized by different study designs and duration of ICS exposure, small study populations, and differences between the used ICS. The aim of this article is to unravel which factors, if any, that contribute to an increased risk of osteoporosis in patients with asthma and to summarize the evidence regarding adverse effects of ICS on bone metabolism, BMD and osteoporotic fractures in patients with asthma.</p>","PeriodicalId":11872,"journal":{"name":"European Clinical Respiratory Journal","volume":null,"pages":null},"PeriodicalIF":1.8000,"publicationDate":"2020-05-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1080/20018525.2020.1763612","citationCount":"11","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Clinical Respiratory Journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/20018525.2020.1763612","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2020/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"RESPIRATORY SYSTEM","Score":null,"Total":0}
引用次数: 11

Abstract

It is well-known that use of continuous systemic corticosteroids (SG) affects bone metabolism, bone mineral density (BMD), and ultimately increases the risk of osteoporosis. In patients with asthma, on the other hand, the effects of long-term high-dose inhaled corticosteroids (ICS) on BMD and risk of osteoporotic fractures is controversial. The reasons for this inconsistency could be explained by the fact that only few long-term studies investigating the effect of ICS in patients with asthma exist. The studies are characterized by different study designs and duration of ICS exposure, small study populations, and differences between the used ICS. The aim of this article is to unravel which factors, if any, that contribute to an increased risk of osteoporosis in patients with asthma and to summarize the evidence regarding adverse effects of ICS on bone metabolism, BMD and osteoporotic fractures in patients with asthma.

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
哮喘患者骨质疏松的风险。
众所周知,持续使用全身皮质类固醇(SG)会影响骨代谢、骨矿物质密度(BMD),并最终增加骨质疏松症的风险。另一方面,在哮喘患者中,长期大剂量吸入皮质类固醇(ICS)对骨密度和骨质疏松性骨折风险的影响存在争议。这种不一致的原因可以用这样一个事实来解释:只有很少的长期研究调查了ICS对哮喘患者的影响。这些研究的特点是研究设计和ICS暴露时间不同,研究人群较小,使用的ICS之间存在差异。本文的目的是揭示哪些因素(如果有的话)导致哮喘患者骨质疏松症的风险增加,并总结有关ICS对哮喘患者骨代谢、骨密度和骨质疏松性骨折的不良影响的证据。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
3.80
自引率
0.00%
发文量
15
审稿时长
16 weeks
期刊最新文献
Comorbid allergy and rhinitis and patient-related outcomes in asthma and COPD: a cross-sectional study. Lung function measurements in the Greenlandic Inuit population: results from the Greenlandic health survey 2017-2019. Asthma severity: the patient's point of view. Comparison of lung volumes measured with computed tomography and whole-body plethysmography - a systematic review. Efficacy and safety of benralizumab in elderly patients with severe eosinophilic asthma.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1